Last week PTC Therapeutics published a paper demonstrating that over 1 year, deflazacort slowed the decline in the distance boys living with Duchenne …
PTC use ataluren trial data to investigate steroidsRead More

31 July 2018 by abzali123
Last week PTC Therapeutics published a paper demonstrating that over 1 year, deflazacort slowed the decline in the distance boys living with Duchenne …
PTC use ataluren trial data to investigate steroidsRead More

26 July 2018 by abzali123
Yesterday, Sarepta Therapeutics announced that the FDA has issued a Clinical Hold letter for the company’s phase I/II trial testing the safety and …

23 July 2018 by abzali123
We have been offered a number of paid internships for young people living with Duchenne. The positions are available this summer across a range of …

19 July 2018 by abzali123
Last week our Director of Campaigns & Strategy, Peter Duffy, attended a meeting at The Medicines and Healthcare products Regulatory …

10 July 2018 by abzali123
Catabasis has announced plans to start a global phase 3 trial to test the safety and effectiveness of a potential drug called edasalonexent in people …
Catabasis announces plans for global trial of edasalonexentRead More

10 July 2018 by abzali123
A huge THANK YOU to the 12 amazing fundraisers who jumped out of planes across the country for Duchenne muscular dystrophy this weekend! YouTube …

5 July 2018 by abzali123
A huge thank you and well done to the incredible Alexis Ellison who completed his 24 hour mammoth bike ride - cycling the 9 mile road back …

27 June 2018 by abzali123
Earlier today Summit Therapeutics announced the results of the PhaseOut DMD clinical trial of Ezutromid. Although Ezutromid was safe and well …
Summit announces results of PhaseOut DMD clinical trial of EzutromidRead More

26 June 2018 by abzali123
ReveraGen BioPharma has announced encouraging preliminary results of their early stage clinical trial of Vamorolone, a potential drug that researchers …
ReveraGen BioPharma announces preliminary results of Vamorolone trialRead More

25 June 2018 by abzali123
We would like to start the week by saying hello and introducing ourselves as your new Action Duchenne team! We are dedicated in delivering our vision …

22 June 2018 by abzali123
Santhera has announced that the MHRA (the UK’s drug and medicines regulator) has granted a renewal of the Early Access to Medicines Scheme scientific …

20 June 2018 by abzali123
Last week our incoming CEO, Shelley Simmonds, completed a 5 day intensive training programme in Barcelona, having been selected to take part in the …
Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA
0300 102 1762
info@actionduchenne.org
